Oncolytic herpes simplex viruses are proving to be effective in clinical trials against a number of cancers. Here, R-115, an oncolytic herpes simplex virus retargeted to human erbB-2, fully virulent in its target cells, and armed with murine interleukin-12 was evaluated in a murine model of glioblastoma. We show that a single R-115 injection in established tumors resulted, in about 30% of animals, in the complete eradication of the tumor, otherwise invariably lethal. The treatment also induced a significant improvement in the overall median survival time of mice and a resistance to recurrence from the same neoplasia. Such a high degree of protection was unprecedented; it was not observed before following treatments with the commonly used, mutated/attenuated oncolytic viruses. This is the first study providing the evidence of benefits offered by a fully virulent, retargeted, and armed herpes simplex virus in the treatment of glioblastoma and paves the way for clinical translation.

中文翻译：

---

在临床前模型中，通过靶向重组溶瘤性HSV的免疫-病毒疗法根除胶质母细胞瘤。

溶瘤性单纯疱疹病毒已被证明在针对多种癌症的临床试验中是有效的。在此，在胶质母细胞瘤的小鼠模型中评估了R-115，它是一种靶向人erbB-2的溶瘤性单纯疱疹病毒，在其靶细胞中具有完全毒性，并配备有鼠白细胞介素12。我们显示，在已建立的肿瘤中单次R-115注射导致大约30％的动物完全根除肿瘤，否则始终致死。该治疗还诱导了小鼠总体中位存活时间的显着改善以及对同一瘤形成的复发的抵抗力。如此高的保护水平是前所未有的。在用常用的突变/减毒溶瘤病毒进行治疗之前，未观察到此现象。